Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries
Elevated blood pressure, a major risk factor for ischemic heart disease, heart failure, and stroke, is the leading global risk for mortality. Treatment and control rates are very low in low- and middle-income countries. There is an urgent need to address this problem. The Global Alliance for Chronic...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
W.B. Saunders
2017
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher View in Scopus |
| LEADER | 04032nam a2201045Ia 4500 | ||
|---|---|---|---|
| 001 | 10.1016-j.ccl.2016.08.010 | ||
| 008 | 220120s2017 CNT 000 0 und d | ||
| 020 | |a 07338651 (ISSN) | ||
| 245 | 1 | 0 | |a Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries |
| 260 | 0 | |b W.B. Saunders |c 2017 | |
| 520 | 3 | |a Elevated blood pressure, a major risk factor for ischemic heart disease, heart failure, and stroke, is the leading global risk for mortality. Treatment and control rates are very low in low- and middle-income countries. There is an urgent need to address this problem. The Global Alliance for Chronic Diseases sponsored research projects focus on controlling hypertension, including community engagement, salt reduction, salt substitution, task redistribution, mHealth, and fixed-dose combination therapies. This paper reviews the rationale for each approach and summarizes the experience of some of the research teams. The studies demonstrate innovative and practical methods for improving hypertension control. © 2016 Elsevier Inc. | |
| 650 | 0 | 4 | |a acetylsalicylic acid |
| 650 | 0 | 4 | |a antihypertensive agent |
| 650 | 0 | 4 | |a Antihypertensive Agents |
| 650 | 0 | 4 | |a blood pressure |
| 650 | 0 | 4 | |a Blood Pressure |
| 650 | 0 | 4 | |a cardiovascular risk |
| 650 | 0 | 4 | |a Community engagement |
| 650 | 0 | 4 | |a Developing Countries |
| 650 | 0 | 4 | |a developing country |
| 650 | 0 | 4 | |a drug combination |
| 650 | 0 | 4 | |a elevated blood pressure |
| 650 | 0 | 4 | |a experimental therapy |
| 650 | 0 | 4 | |a fixed dose combination |
| 650 | 0 | 4 | |a health auxiliary |
| 650 | 0 | 4 | |a health care distribution |
| 650 | 0 | 4 | |a human |
| 650 | 0 | 4 | |a Humans |
| 650 | 0 | 4 | |a hydroxymethylglutaryl coenzyme A reductase inhibitor |
| 650 | 0 | 4 | |a hypertension |
| 650 | 0 | 4 | |a Hypertension |
| 650 | 0 | 4 | |a incidence |
| 650 | 0 | 4 | |a Incidence |
| 650 | 0 | 4 | |a Low- and middle-income countries |
| 650 | 0 | 4 | |a low income country |
| 650 | 0 | 4 | |a meta analysis (topic) |
| 650 | 0 | 4 | |a mHealth |
| 650 | 0 | 4 | |a middle income country |
| 650 | 0 | 4 | |a mobile health |
| 650 | 0 | 4 | |a mobile phone |
| 650 | 0 | 4 | |a pathophysiology |
| 650 | 0 | 4 | |a Polypill |
| 650 | 0 | 4 | |a priority journal |
| 650 | 0 | 4 | |a procedures |
| 650 | 0 | 4 | |a randomized controlled trial (topic) |
| 650 | 0 | 4 | |a Review |
| 650 | 0 | 4 | |a risk factor |
| 650 | 0 | 4 | |a Risk Factors |
| 650 | 0 | 4 | |a Salt reduction |
| 650 | 0 | 4 | |a Salt substitution |
| 650 | 0 | 4 | |a sodium restriction |
| 650 | 0 | 4 | |a substitution therapy |
| 650 | 0 | 4 | |a Task redistribution |
| 650 | 0 | 4 | |a telemedicine |
| 650 | 0 | 4 | |a Telemedicine |
| 700 | 1 | 0 | |a Bernabe-Ortiz, A. |e author |
| 700 | 1 | 0 | |a Fuster, V. |e author |
| 700 | 1 | 0 | |a Gyamfi, J. |e author |
| 700 | 1 | 0 | |a Herasme, O.I. |e author |
| 700 | 1 | 0 | |a Ieremia, M. |e author |
| 700 | 1 | 0 | |a Johnson, C. |e author |
| 700 | 1 | 0 | |a Joshi, R. |e author |
| 700 | 1 | 0 | |a Kamano, J.H. |e author |
| 700 | 1 | 0 | |a Lazo-Porras, M. |e author |
| 700 | 1 | 0 | |a Limbani, F. |e author |
| 700 | 1 | 0 | |a Liu, P. |e author |
| 700 | 1 | 0 | |a Lopez-Jaramillo, P. |e author |
| 700 | 1 | 0 | |a McCready, T. |e author |
| 700 | 1 | 0 | |a Miranda, J.J. |e author |
| 700 | 1 | 0 | |a Mohan, S. |e author |
| 700 | 1 | 0 | |a Ogedegbe, O. |e author |
| 700 | 1 | 0 | |a Oldenburg, B. |e author |
| 700 | 1 | 0 | |a Ovbiagele, B. |e author |
| 700 | 1 | 0 | |a Owolabi, M. |e author |
| 700 | 1 | 0 | |a Peiris, D. |e author |
| 700 | 1 | 0 | |a Pillay, A. |e author |
| 700 | 1 | 0 | |a Ponce-Lucero, V. |e author |
| 700 | 1 | 0 | |a Praveen, D. |e author |
| 700 | 1 | 0 | |a Schwalm, J.-D. |e author |
| 700 | 1 | 0 | |a Thrift, A.G. |e author |
| 700 | 1 | 0 | |a Tobe, S.W. |e author |
| 700 | 1 | 0 | |a Trieu, K. |e author |
| 700 | 1 | 0 | |a Vedanthan, R. |e author |
| 700 | 1 | 0 | |a Webster, J. |e author |
| 700 | 1 | 0 | |a Webster, R. |e author |
| 700 | 1 | 0 | |a Yeates, K. |e author |
| 700 | 1 | 0 | |a Yusoff, K. |e author |
| 773 | |t Cardiology Clinics |x 07338651 (ISSN) |g 35 1, 99-115 | ||
| 856 | |z View Fulltext in Publisher |u https://doi.org/10.1016/j.ccl.2016.08.010 | ||
| 856 | |z View in Scopus |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996993001&doi=10.1016%2fj.ccl.2016.08.010&partnerID=40&md5=f8a9479c6ce776e80800f3c655557a4d | ||